Wikipedia -WSS

Wikipedia

author：knowledge 2025-10-02 00:28:16 - browse：72789

Illustration of three connected puzzle pieces, with a woman standing near the missing/empty puzzle piece space. -- first opinion coverage from STAT — Adobe

Women have always been underrepresented in medical research. A new study reveals that not much has changed, especially when it comes to tests of cardiovascular devices.

In a paper published in JAMA Internal Medicine on Monday, researchers found that the percentage of women represented in high-risk medical device trials did not increase from 2010 to 2020. Women generally made up just 33% of participants when the team reviewed 195 trials published from 2016 to 2022. The percentages varied between devices: Women made up 46% of participants in orthopedic trials, but 29% in cardiovascular studies.

The issue isn’t new. The government has made some strides in correcting earlier missteps, like the Food and Drug Administration telling researchers in 1977 to exclude women of reproductive potential from early clinical trials. But stakeholders think agencies like the FDA could do more to incentivize the enrollment of women.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： ASCO: AstraZeneca says CAR

WSS

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

At Orexo, a ‘turning point’ for everything but digital health

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Google and Epic fight stronger regulation of AI in health care

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Why hospitals are withdrawing from US News rankings

focus

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

The high cost of giving birth even with insurance

BMI, flaws aside, is found to be useful estimate of body fat in youth

State Dept. review finds Biden bears some blame for Afghanistan failures

At ASCO, AstraZeneca reports strong data for breast cancer drug

United colonoscopy coverage change 'may cost lives,' doctors say

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Hollywood unions extend contract negotiations for actors

Letters to First Opinion on caregivers, digital health, and more

Malaria cases in Florida and Texas: Here’s what you need to know

FDA's Pazdur wants cancer trials to range beyond China alone

hotspot

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

At ASCO, AstraZeneca reports strong data for breast cancer drug

Why hospitals are withdrawing from US News rankings

Sanofi seeks simpler, safer CRISPR sickle cell cure

Startup Neumora takes a novel depression drug to Phase 3

Google and Epic fight stronger regulation of AI in health care

explore

focus

hotspot

focus